Merrill Lynch Stick to The Buy Rating of theirs for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is more or less 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the very first quarter of 2021.

The present opinion among eleven TipRanks analysts is actually for a moderate Buy rating of shares in CVS Health, with an average price target of eighty four dolars.

The analysts price targets range from a high of hundred one dolars to a low of sixty one dolars.

In the newest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is actually $99.57 billion.

Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management strategies. The Long or retail Term Care segment includes offering of prescription medications and assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioural health, medical management capabilities. The Corporate segment involves in providing administrative services and management. The company was created by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.